\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\\ \\ not\\ available\ \(0\)\
\-\ laboratory\\:\\-\\-\\ 3\\ oligoclonal\\ bands\\ seen\\ in\\ csf\\;\\ no\\ oligoclonal\\ bands\\ present\\ in\\ serum\\-\\-\\ serum\\ cardiolipin\\ igg\\,\\ igm\\,\\ iga\\ negative\\-\\-\\ ds\\ dna\\ ab\\ positive\\ \\(28\\ iu\\/ml\\)\\-\\-\\ ena\\ negative\\-\\-\\ lyme\\ ab\\ total\\ borderline\\;\\ b\\.\\ burgdorferi\\ igg\\,\\ igm\\ negative\ \(0\)\
\-\ there\\ are\\ multifocal\\ areas\\ of\\ predominately\\ white\\ matter\\ abnormal\\ signal\\ intensity\\ \\ several\\ lesions\\ are\\ in\\ the\\ corpus\\ callosum\\,\\ the\\ largest\\ seen\\ in\\ the\\ body\\ of\\ the\\ corpus\\ callosum\\;\\ with\\ periventricular\\ and\\ periatrial\\ predominance\\.\\ \\ \ \(0\)\
\-\ several\\ lesions\\ are\\ oriented\\ perpendicular\\ to\\ the\\ corpus\\ callosum\\ \\(dawson\\â\\€\\™s\\ fingers\\)\\.\\ \ \(0\)\
\-\ similar\\ hyperintense\\ lesions\\ are\\ also\\ seen\\ in\\ the\\ brain\\ stem\\ and\\ spinal\\ cord\\,\\ best\\ seen\\ on\\ the\\ sagittal\\ images\\.\ \(0\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ 1\\.\\ \\ cerebral\\ autosomal\\ dominant\\ arteriopathy\\ with\\ subcortical\\ infarct\\ \\(cadasil\\)\ \(0\)\
\-\ 2\\.\\ \\ lyme\\ disease\ \(0\)\
\-\ 3\\.\\ \\ central\\ nervous\\ system\\ vasculitis\ \(0\)\
\-\ 4\\.\\ \\ multiple\\ sclerosis\ \(0\)\
\-\ 5\\.\\ adem\\ \\(acute\\ disseminated\\ encephalomyelitis\ \(0\)\
\-\ 25\\ y\\/o\\ woman\\ has\\ left\\ ue\\ weakness\\ and\\ chorea\\;\\ with\\ sensory\\ loss\\ to\\ her\\ left\\ arm\\.\\ \\ rapidly\\ worsening\\ of\\ spasm\\ in\\ the\\ wrist\\ and\\ hand\\.\ \(0\)\
\-\ multiple\\ sclerosis\\ \\(ms\\)\\ is\\ a\\ multifocal\\ disease\\ with\\ a\\ complex\\ pathogenesis\\ that\\ includes\\ inflammation\\ and\\ potentially\\ disabling\\ focal\\ lesions\\ that\\ disseminate\\ throughout\\ the\\ central\\ nervous\\ system\\.\\ \\ it\\ is\\ the\\ most\\ common\\ primary\\ myelin\\ disorder\\,\\ with\\ an\\ estimated\\ patient\\ prevalence\\ of\\ 250\\,000\\ to\\ 350\\,000\\ in\\ the\\ united\\ states\\.\\ \\ eighty\\ percent\\ of\\ patients\\ have\\ relapsing\\-remitting\\ ms\\,\\ and\\ the\\ minority\\ of\\ patients\\ has\\ primary\\ progressive\\ ms\\.\\ \\ this\\ subtype\\ of\\ ms\\ usually\\ begins\\ in\\ the\\ second\\ or\\ third\\ decade\\ of\\ life\\ and\\ has\\ a\\ female\\ predominance\\ of\\ approximately\\ 2\\:1\\.\\ \\ the\\ prevalence\\ is\\ highest\\ in\\ northern\\ europe\\,\\ however\\,\\ the\\ occurrence\\ of\\ rapid\\ shifts\\ in\\ the\\ incidence\\ of\\ ms\\ have\\ been\\ reported\\ in\\ recent\\ studies\\.\ \(0\)\
\-\ the\\ pathogenesis\\ of\\ ms\\ remains\\ unclear\\ today\\.\\ \\ however\\,\\ a\\ multifactorial\\ pathogenetic\\ mechanism\\ has\\ been\\ postulated\\ given\\ the\\ heterogeneity\\ of\\ clinical\\,\\ genetic\\,\\ and\\ radiological\\ studies\\ of\\ ms\\.\\ \\ the\\ pathological\\ hallmark\\ of\\ chronic\\ ms\\ is\\ the\\ demyelinated\\ plaque\\,\\ which\\ consisted\\ of\\ a\\ well\\-demarcated\\ hypocellular\\ area\\ characterized\\ by\\ the\\ loss\\ of\\ myelin\\,\\ relative\\ preservation\\ of\\ axons\\,\\ and\\ the\\ formation\\ of\\ astrocytic\\ scars\\.\\ \\ lesions\\ have\\ a\\ predilection\\ for\\ the\\ optic\\ nerves\\,\\ periventreicular\\ white\\ matter\\,\\ brain\\ stem\\,\\ cerebellum\\,\\ and\\ spinal\\ cord\\ white\\ matter\\.\\ \\ lesions\\ are\\ usually\\ round\\ or\\ ovoid\\,\\ thought\\ they\\ may\\ also\\ have\\ finger\\-like\\ extensions\\ along\\ the\\ path\\ of\\ small\\ or\\ medium\\-sized\\ blood\\ vessels\\ \\(dawson\\â\\€\\™s\\ fingers\\)\\.\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\	the\\ diagnosis\\ of\\ multiple\\ sclerosis\\ is\\ based\\ on\\ established\\ clinical\\,\\ laboratory\\ and\\ radiological\\ findings\\.\\ \\ patients\\ with\\ the\\ relapsing\\ forms\\ of\\ multiple\\ sclerosis\\ usually\\ present\\ with\\ sensory\\ disturbances\\,\\ unilateral\\ optic\\ neuritis\\,\\ diplopia\\,\\ limb\\ weakness\\,\\ gait\\ ataxia\\,\\ and\\ neurogenic\\ bladder\\ and\\ bowel\\.\\ \\ prominent\\ cortical\\ signs\\ and\\ extrapyamidal\\ phenomena\\ can\\ also\\ present\\ but\\ are\\ rarely\\ predominant\\ features\\ of\\ the\\ clinical\\ presentation\\.\\ \\ laboratory\\ workup\\ typically\\ includes\\ a\\ cerebrospinal\\ fluid\\ analysis\\,\\ which\\ often\\ shows\\ increased\\ intrathecal\\ synthesis\\ of\\ immunoglobulins\\ of\\ restricted\\ specificity\\ \\(oligoclonal\\ bands\\ of\\ igg\\)\\ with\\ moderate\\ lymphocytic\\ pleocytosis\\.\\ \\ cole\\ and\\ colleagues\\ have\\ suggested\\ that\\ the\\ presence\\ of\\ oligoclonal\\ bands\\ in\\ cerebrospinal\\ fluid\\ slightly\\ increases\\ the\\ risk\\ of\\ recurrent\\ disease\\.\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\	mri\\ is\\ the\\ preferred\\ imaging\\ modality\\ to\\ study\\ suspected\\ ms\\ as\\ it\\ depicts\\ the\\ frequency\\,\\ shape\\,\\ and\\ location\\ of\\ the\\ characteristic\\ ms\\ lesions\\.\\ \\ these\\ lesions\\ have\\ discrete\\ foci\\ with\\ well\\-defined\\ margins\\ that\\ are\\ commonly\\ located\\ in\\ a\\ periventricular\\ location\\,\\ in\\ the\\ deep\\ white\\ matter\\,\\ adjacent\\ to\\ the\\ atria\\,\\ occipital\\ horns\\,\\ and\\ the\\ body\\ of\\ the\\ lateral\\ ventricles\\.\\ \\ t2\\-weighted\\ images\\ reflect\\ a\\ broad\\ spectrum\\ of\\ pathological\\ changes\\,\\ including\\ inflammation\\,\\ edema\\,\\ demyelination\\,\\ gliosis\\,\\ and\\ axonal\\ loss\\.\\ \\ many\\ of\\ the\\ hyperintense\\ t2\\-weighted\\ lesions\\ have\\ little\\ clinical\\ significance\\,\\ as\\ they\\ are\\ more\\ likely\\ to\\ be\\ chronic\\ ms\\ lesions\\.\\ \\ hence\\,\\ there\\ is\\ no\\ correlation\\ with\\ the\\ number\\ of\\ brain\\ lesions\\ detected\\ with\\ a\\ t2\\-weighted\\ sequence\\ and\\ the\\ patient\\â\\€\\™s\\ level\\ of\\ functional\\ disability\\.\\ \\ studies\\ have\\ shown\\ that\\ fluid\\-attenuated\\ inversion\\ recovery\\ \\(flair\\)\\ sequences\\ are\\ superior\\ to\\ t2\\-weighted\\ images\\ for\\ detecting\\ ms\\ brain\\ lesions\\ as\\ it\\ can\\ detect\\ many\\ cortical\\ and\\ juxtacortial\\ lesions\\ in\\ ms\\,\\ which\\ may\\ present\\ in\\ secondary\\ progressive\\ disease\\ and\\ often\\ missed\\ by\\ other\\ sequences\\.\\ \\ furthermore\\,\\ gadolinium\\-dtpa\\ injection\\,\\ a\\ paramagnetic\\ contrast\\ agent\\ that\\ crosses\\ only\\ disrupted\\ blood\\-brain\\-barrier\\,\\ may\\ demonstrate\\ foci\\ of\\ demyelination\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ms\\:\\ 0\\.07905632671760693\ \(0\)\
\-\ lesions\\:\\ 0\\.03959825110848378\ \(0\)\
\-\ oligoclonal\\:\\ 0\\.03468939190930734\ \(0\)\
\-\ bands\\:\\ 0\\.027174148374232706\ \(0\)\
\-\ \\-\\-\\:\\ 0\\.026132951369805223\ \(0\)\
\-\ igg\\:\\ 0\\.023453047049800498\ \(0\)\
\-\ t2\\-weighted\\:\\ 0\\.023045976320822153\ \(0\)\
\-\ dawson\\:\\ 0\\.020551015007452433\ \(0\)\
\-\ sclerosis\\:\\ 0\\.02043485508273199\ \(0\)\
\-\ have\\:\\ 0\\.019711723870733337\ \(0\)\
\-\ matter\\:\\ 0\\.01791999984234779\ \(0\)\
\-\ myelin\\:\\ 0\\.017625283213396216\ \(0\)\
\-\ callosum\\:\\ 0\\.017515452563741082\ \(0\)\
\-\ corpus\\:\\ 0\\.01681896766169803\ \(0\)\
\-\ igm\\:\\ 0\\.016645989524647034\ \(0\)\
\-\ cerebrospinal\\:\\ 0\\.016645989524647034\ \(0\)\
\-\ \\,\\:\\ 0\\.015860509830573428\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.015635364699867\ \(0\)\
\-\ ab\\:\\ 0\\.015368830855507524\ \(0\)\
\-\ nervous\\:\\ 0\\.01512656247147097\ \(0\)\
\-\ demyelination\\:\\ 0\\.01512656247147097\ \(0\)\
\-\ white\\:\\ 0\\.015095095673566008\ \(0\)\
\-\ predominance\\:\\ 0\\.014247090602308313\ \(0\)\
\-\ lyme\\:\\ 0\\.014085640211319141\ \(0\)\
\-\ prevalence\\:\\ 0\\.014008443042548828\ \(0\)\
\-\ clinical\\:\\ 0\\.01400431318277499\ \(0\)\
\-\ are\\:\\ 0\\.01395987330594729\ \(0\)\
\-\ brain\\:\\ 0\\.013695613972318306\ \(0\)\
\-\ fingers\\:\\ 0\\.013652833474973534\ \(0\)\
\-\ stem\\:\\ 0\\.013522899615667456\ \(0\)\
\-\ pathological\\:\\ 0\\.013280631231630901\ \(0\)\
\-\ radiological\\:\\ 0\\.013167290048092166\ \(0\)\
\-\ periventricular\\:\\ 0\\.013112378497618832\ \(0\)\
\-\ studies\\:\\ 0\\.012749004997786258\ \(0\)\
\-\ laboratory\\:\\ 0\\.012579594151214644\ \(0\)\
\-\ multifocal\\:\\ 0\\.012239708971479073\ \(0\)\
\-\ multiple\\:\\ 0\\.011982729716905918\ \(0\)\
\-\ that\\:\\ 0\\.011792122997806844\ \(0\)\
\-\ sensory\\:\\ 0\\.011773819625283781\ \(0\)\
\-\ 350\\,000\\:\\ 0\\.011738373400754325\ \(0\)\
\-\ eighty\\:\\ 0\\.011738373400754325\ \(0\)\
\-\ relapsing\\-remitting\\:\\ 0\\.011738373400754325\ \(0\)\
\-\ pathogenetic\\:\\ 0\\.011738373400754325\ \(0\)\
\-\ demyelinated\\:\\ 0\\.011738373400754325\ \(0\)\
\-\ periventreicular\\:\\ 0\\.011738373400754325\ \(0\)\
\-\ extrapyamidal\\:\\ 0\\.011738373400754325\ \(0\)\
\-\ cole\\:\\ 0\\.011738373400754325\ \(0\)\
\-\ juxtacortial\\:\\ 0\\.011738373400754325\ \(0\)\
\-\ serum\\:\\ 0\\.01098314391940707\ \(0\)\
\-\ burgdorferi\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ periatrial\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ cadasil\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ chorea\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ 250\\,000\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ 2\\:1\\.\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ northern\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ hypocellular\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ finger\\-like\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ extensions\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ medium\\-sized\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ colleagues\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ paramagnetic\\:\\ 0\\.010815407780834292\ \(0\)\
\-\ \\;\\:\\ 0\\.010787862521718209\ \(0\)\
\-\ optic\\:\\ 0\\.01053450338110473\ \(0\)\
\-\ usually\\:\\ 0\\.010365891826365216\ \(0\)\
\-\ present\\:\\ 0\\.010279673789249965\ \(0\)\
\-\ ds\\:\\ 0\\.010275507503726217\ \(0\)\
\-\ ena\\:\\ 0\\.010275507503726217\ \(0\)\
\-\ disseminate\\:\\ 0\\.010275507503726217\ \(0\)\
\-\ shifts\\:\\ 0\\.010275507503726217\ \(0\)\
\-\ fluid\\-attenuated\\:\\ 0\\.010275507503726217\ \(0\)\
\-\ blood\\-brain\\-barrier\\:\\ 0\\.010275507503726217\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.010202503620421263\ \(0\)\
\-\ negative\\:\\ 0\\.010194887462216543\ \(0\)\
\-\ loss\\:\\ 0\\.009908645162989772\ \(0\)\
\-\ cardiolipin\\:\\ 0\\.009892442160914259\ \(0\)\
\-\ multifactorial\\:\\ 0\\.009892442160914259\ \(0\)\
\-\ pleocytosis\\:\\ 0\\.009892442160914259\ \(0\)\
\-\ depicts\\:\\ 0\\.009892442160914259\ \(0\)\
\-\ gadolinium\\-dtpa\\:\\ 0\\.009892442160914259\ \(0\)\
\-\ s\\:\\ 0\\.009790017312042291\ \(0\)\
\-\ foci\\:\\ 0\\.009768372695480813\ \(0\)\
\-\ inflammation\\:\\ 0\\.009677056920571008\ \(0\)\
\-\ iu\\/ml\\:\\ 0\\.00959531359724687\ \(0\)\
\-\ arteriopathy\\:\\ 0\\.00959531359724687\ \(0\)\
\-\ minority\\:\\ 0\\.00959531359724687\ \(0\)\
\-\ astrocytic\\:\\ 0\\.00959531359724687\ \(0\)\
\-\ synthesis\\:\\ 0\\.00959531359724687\ \(0\)\
\-\ sequences\\:\\ 0\\.009503313853012016\ \(0\)\
\-\ hyperintense\\:\\ 0\\.009447830266053716\ \(0\)\
\-\ many\\:\\ 0\\.009353431467130286\ \(0\)\
\-\ postulated\\:\\ 0\\.009352541883806183\ \(0\)\
\-\ axons\\:\\ 0\\.009352541883806183\ \(0\)\
\-\ relapsing\\:\\ 0\\.009352541883806183\ \(0\)\
\-\ includes\\:\\ 0\\.009174115568146034\ \(0\)\
\-\ europe\\:\\ 0\\.009147281324781872\ \(0\)\
\-\ immunoglobulins\\:\\ 0\\.009147281324781872\ \(0\)\
\-\ progressive\\:\\ 0\\.008994511624615986\ \(0\)\
\-\ seen\\:\\ 0\\.008994021917803944\ \(0\)\
\-\ in\\:\\ 0\\.008977837126823008\ \(0\)\
\-\ dna\\:\\ 0\\.008969476540994224\ \(0\)\
\-\ disabling\\:\\ 0\\.008969476540994224\ \(0\)\
\-\ system\\:\\ 0\\.008959999921173896\ \(0\)\
\-\ patients\\:\\ 0\\.008834519038745776\ \(0\)\
\-\ iga\\:\\ 0\\.008812641606698108\ \(0\)\
\-\ hallmark\\:\\ 0\\.008672347977326834\ \(0\)\
\-\ intrathecal\\:\\ 0\\.008672347977326834\ \(0\)\
\-\ axonal\\:\\ 0\\.008672347977326834\ \(0\)\
\-\ cord\\:\\ 0\\.008647600320120909\ \(0\)\
\-\ has\\:\\ 0\\.008547003837519457\ \(0\)\
\-\ weakness\\:\\ 0\\.008451694681833249\ \(0\)\
\-\ ue\\:\\ 0\\.008429576263886148\ \(0\)\
\-\ highest\\:\\ 0\\.008429576263886148\ \(0\)\
\-\ well\\-demarcated\\:\\ 0\\.008429576263886148\ \(0\)\
\-\ phenomena\\:\\ 0\\.008429576263886148\ \(0\)\
\-\ reflect\\:\\ 0\\.008429576263886148\ \(0\)\
\-\ atria\\:\\ 0\\.008322994762323517\ \(0\)\
\-\ cortical\\:\\ 0\\.008295805194609353\ \(0\)\
\-\ heterogeneity\\:\\ 0\\.008224315704861837\ \(0\)\
\-\ they\\:\\ 0\\.008199590217010137\ \(0\)\
\-\ spinal\\:\\ 0\\.00814853850966601\ \(0\)\
\-\ perpendicular\\:\\ 0\\.008132447700218759\ \(0\)\
\-\ consisted\\:\\ 0\\.007965785725579605\ \(0\)\
\-\ gliosis\\:\\ 0\\.007965785725579605\ \(0\)\
\-\ crosses\\:\\ 0\\.007965785725579605\ \(0\)\
\-\ location\\:\\ 0\\.007937969871914497\ \(0\)\
\-\ \\(\\:\\ 0\\.0076949318374845335\ \(0\)\
\-\ subtype\\:\\ 0\\.007684415427753762\ \(0\)\
\-\ disrupted\\:\\ 0\\.007684415427753762\ \(0\)\
\-\ it\\:\\ 0\\.00767316265459261\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.0076224713323677536\ \(0\)\
\-\ scars\\:\\ 0\\.0076224713323677536\ \(0\)\
\-\ borderline\\:\\ 0\\.007506610643966115\ \(0\)\
\-\ predilection\\:\\ 0\\.007506610643966115\ \(0\)\
\-\ detecting\\:\\ 0\\.007506610643966115\ \(0\)\
\-\ central\\:\\ 0\\.007487700018268866\ \(0\)\
\-\ may\\:\\ 0\\.007487330368434583\ \(0\)\
\-\ occurrence\\:\\ 0\\.007452253793739411\ \(0\)\
\-\ today\\:\\ 0\\.007452253793739411\ \(0\)\
\-\ disturbances\\:\\ 0\\.007452253793739411\ \(0\)\
\-\ hence\\:\\ 0\\.007452253793739411\ \(0\)\
\-\ disease\\:\\ 0\\.007439347756142233\ \(0\)\
\-\ specificity\\:\\ 0\\.007400029142403484\ \(0\)\
\-\ body\\:\\ 0\\.007390848768812476\ \(0\)\
\-\ predominant\\:\\ 0\\.007349775709669999\ \(0\)\
\-\ several\\:\\ 0\\.007315826459979728\ \(0\)\
\-\ predominately\\:\\ 0\\.0073013500849418034\ \(0\)\
\-\ agent\\:\\ 0\\.0073013500849418034\ \(0\)\
\-\ often\\:\\ 0\\.007260914909506398\ \(0\)\
\-\ unclear\\:\\ 0\\.007254623960026663\ \(0\)\
\-\ lymphocytic\\:\\ 0\\.007254623960026663\ \(0\)\
\-\ significance\\:\\ 0\\.007254623960026663\ \(0\)\
\-\ path\\:\\ 0\\.007209482080298726\ \(0\)\
\-\ neuritis\\:\\ 0\\.007209482080298726\ \(0\)\
\-\ inversion\\:\\ 0\\.007209482080298726\ \(0\)\
\-\ missed\\:\\ 0\\.007209482080298726\ \(0\)\
\-\ the\\:\\ 0\\.007179390284209596\ \(0\)\
\-\ horns\\:\\ 0\\.0071658205319325595\ \(0\)\
\-\ begins\\:\\ 0\\.007082571055259678\ \(0\)\
\-\ disability\\:\\ 0\\.007082571055259678\ \(0\)\
\-\ united\\:\\ 0\\.007004221521274414\ \(0\)\
\-\ preservation\\:\\ 0\\.007004221521274414\ \(0\)\
\-\ neurogenic\\:\\ 0\\.007004221521274414\ \(0\)\
\-\ established\\:\\ 0\\.0069667103668580406\ \(0\)\
\-\ furthermore\\:\\ 0\\.0069667103668580406\ \(0\)\
\-\ subcortical\\:\\ 0\\.0069302270457020955\ \(0\)\
\-\ disseminated\\:\\ 0\\.0069302270457020955\ \(0\)\
\-\ detect\\:\\ 0\\.006894716730013466\ \(0\)\
\-\ adem\\:\\ 0\\.006860128865295409\ \(0\)\
\-\ plaque\\:\\ 0\\.006860128865295409\ \(0\)\
\-\ b\\.\\:\\ 0\\.006761449807833728\ \(0\)\
\-\ preferred\\:\\ 0\\.006761449807833728\ \(0\)\
\-\ primary\\:\\ 0\\.006741369541666303\ \(0\)\
\-\ also\\:\\ 0\\.006729505700413387\ \(0\)\
\-\ decade\\:\\ 0\\.0066995057124477194\ \(0\)\
\-\ potentially\\:\\ 0\\.006669581803190651\ \(0\)\
\-\ increases\\:\\ 0\\.006669581803190651\ \(0\)\
\-\ \\)\\:\\ 0\\.0066508173698976505\ \(0\)\
\-\ diplopia\\:\\ 0\\.006640315615815451\ \(0\)\
\-\ forms\\:\\ 0\\.006611678857864767\ \(0\)\
\-\ autosomal\\:\\ 0\\.006583645024046083\ \(0\)\
\-\ estimated\\:\\ 0\\.006583645024046083\ \(0\)\
\-\ spectrum\\:\\ 0\\.006583645024046083\ \(0\)\
\-\ discrete\\:\\ 0\\.006556189248809416\ \(0\)\
\-\ images\\:\\ 0\\.0065483244685060745\ \(0\)\
\-\ fluid\\:\\ 0\\.006467747282566853\ \(0\)\
\-\ largest\\:\\ 0\\.006451699747555762\ \(0\)\
\-\ sequence\\:\\ 0\\.006451699747555762\ \(0\)\
\-\ limb\\:\\ 0\\.006426810089749966\ \(0\)\
\-\ chronic\\:\\ 0\\.006410092231443409\ \(0\)\
\-\ spasm\\:\\ 0\\.006378384465021769\ \(0\)\
\-\ which\\:\\ 0\\.006372082239317772\ \(0\)\
\-\ however\\:\\ 0\\.006336532771230548\ \(0\)\
\-\ rapidly\\:\\ 0\\.006308896111931796\ \(0\)\
\-\ ovoid\\:\\ 0\\.0062645067374077065\ \(0\)\
\-\ correlation\\:\\ 0\\.0062645067374077065\ \(0\)\
\-\ functional\\:\\ 0\\.0062645067374077065\ \(0\)\
\-\ modality\\:\\ 0\\.006242854912012526\ \(0\)\
\-\ genetic\\:\\ 0\\.006221549530725654\ \(0\)\
\-\ percent\\:\\ 0\\.006200579681234123\ \(0\)\
\-\ recovery\\:\\ 0\\.006200579681234123\ \(0\)\
\-\ been\\:\\ 0\\.0061911981077602965\ \(0\)\
\-\ little\\:\\ 0\\.00617993495881606\ \(0\)\
\-\ ataxia\\:\\ 0\\.00608125590135438\ \(0\)\
\-\ frequency\\:\\ 0\\.006007261425782062\ \(0\)\
\-\ detected\\:\\ 0\\.006007261425782062\ \(0\)\
\-\ remains\\:\\ 0\\.005920200494673072\ \(0\)\
\-\ shape\\:\\ 0\\.005920200494673072\ \(0\)\
\-\ broad\\:\\ 0\\.005903451117566733\ \(0\)\
\-\ mechanism\\:\\ 0\\.005854431179986552\ \(0\)\
\-\ workup\\:\\ 0\\.005854431179986552\ \(0\)\
\-\ well\\-defined\\:\\ 0\\.005854431179986552\ \(0\)\
\-\ vasculitis\\:\\ 0\\.005822725922072146\ \(0\)\
\-\ a\\:\\ 0\\.005809051691084706\ \(0\)\
\-\ dominant\\:\\ 0\\.00580715196766044\ \(0\)\
\-\ analysis\\:\\ 0\\.005791758062998555\ \(0\)\
\-\ suggested\\:\\ 0\\.005791758062998555\ \(0\)\
\-\ nerves\\:\\ 0\\.005776540092527685\ \(0\)\
\-\ rapid\\:\\ 0\\.005746616183270617\ \(0\)\
\-\ number\\:\\ 0\\.005674622546426042\ \(0\)\
\-\ characterized\\:\\ 0\\.005660679404126049\ \(0\)\
\-\ cerebellum\\:\\ 0\\.005660679404126049\ \(0\)\
\-\ unilateral\\:\\ 0\\.005646880752946892\ \(0\)\
\-\ oriented\\:\\ 0\\.005579954208631461\ \(0\)\
\-\ rarely\\:\\ 0\\.005455418845101736\ \(0\)\
\-\ of\\:\\ 0\\.005429604564486811\ \(0\)\
\-\ relative\\:\\ 0\\.005420221432228027\ \(0\)\
\-\ 28\\:\\ 0\\.005363550840458659\ \(0\)\
\-\ states\\:\\ 0\\.005352500503821248\ \(0\)\
\-\ ventricles\\:\\ 0\\.005352500503821248\ \(0\)\
\-\ occipital\\:\\ 0\\.005309193990231954\ \(0\)\
\-\ injection\\:\\ 0\\.005309193990231954\ \(0\)\
\-\ gait\\:\\ 0\\.00529858391080562\ \(0\)\
\-\ wrist\\:\\ 0\\.005256969338896027\ \(0\)\
\-\ is\\:\\ 0\\.005241059186009427\ \(0\)\
\-\ thought\\:\\ 0\\.005236639815419611\ \(0\)\
\-\ restricted\\:\\ 0\\.005236639815419611\ \(0\)\
\-\ incidence\\:\\ 0\\.005216616010673219\ \(0\)\
\-\ flair\\:\\ 0\\.005216616010673219\ \(0\)\
\-\ margins\\:\\ 0\\.005167835540393883\ \(0\)\
\-\ as\\:\\ 0\\.005163425456301443\ \(0\)\
\-\ can\\:\\ 0\\.005161710659038801\ \(0\)\
\-\ disorder\\:\\ 0\\.005111564156519206\ \(0\)\
\-\ infarct\\:\\ 0\\.0050487854901733985\ \(0\)\
\-\ and\\:\\ 0\\.0050335407728050435\ \(0\)\
\-\ life\\:\\ 0\\.004963944192721857\ \(0\)\
\-\ round\\:\\ 0\\.004915518567993661\ \(0\)\
\-\ 5\\.\\:\\ 0\\.0049076161238927095\ \(0\)\
\-\ total\\:\\ 0\\.004899760302152113\ \(0\)\
\-\ suspected\\:\\ 0\\.004899760302152113\ \(0\)\
\-\ characteristic\\:\\ 0\\.00481627349227786\ \(0\)\
\-\ features\\:\\ 0\\.004801640840379598\ \(0\)\
\-\ recurrent\\:\\ 0\\.004801640840379598\ \(0\)\
\-\ best\\:\\ 0\\.004787167242194639\ \(0\)\
\-\ arm\\:\\ 0\\.0047657476180247\ \(0\)\
\-\ csf\\:\\ 0\\.004751656926506008\ \(0\)\
\-\ formation\\:\\ 0\\.004696739538311536\ \(0\)\
\-\ located\\:\\ 0\\.00468335693397931\ \(0\)\
\-\ hand\\:\\ 0\\.004676715733565143\ \(0\)\
\-\ prominent\\:\\ 0\\.004670107492097594\ \(0\)\
\-\ bladder\\:\\ 0\\.004618390004326271\ \(0\)\
\-\ deep\\:\\ 0\\.004605768507715694\ \(0\)\
\-\ 25\\:\\ 0\\.004599502341221136\ \(0\)\
\-\ slightly\\:\\ 0\\.004599502341221136\ \(0\)\
\-\ vessels\\:\\ 0\\.004580878849909898\ \(0\)\
\-\ third\\:\\ 0\\.004562512242543272\ \(0\)\
\-\ shown\\:\\ 0\\.004562512242543272\ \(0\)\
\-\ complex\\:\\ 0\\.004556445908940263\ \(0\)\
\-\ sagittal\\:\\ 0\\.004538410988690253\ \(0\)\
\-\ 4\\.\\:\\ 0\\.004479999960586948\ \(0\)\
\-\ worsening\\:\\ 0\\.004479999960586948\ \(0\)\
\-\ moderate\\:\\ 0\\.004474297348347266\ \(0\)\
\-\ similar\\:\\ 0\\.004462964872091729\ \(0\)\
\-\ second\\:\\ 0\\.004370344787268945\ \(0\)\
\-\ based\\:\\ 0\\.004339134969729642\ \(0\)\
\-\ commonly\\:\\ 0\\.004293650390753185\ \(0\)\
\-\ throughout\\:\\ 0\\.004259317345272872\ \(0\)\
\-\ reported\\:\\ 0\\.004147902597304676\ \(0\)\
\-\ presence\\:\\ 0\\.0041302072149895196\ \(0\)\
\-\ risk\\:\\ 0\\.004121446933900249\ \(0\)\
\-\ intensity\\:\\ 0\\.004112743909959123\ \(0\)\
\-\ including\\:\\ 0\\.004108413636475265\ \(0\)\
\-\ typically\\:\\ 0\\.004016545631832187\ \(0\)\
\-\ signs\\:\\ 0\\.004004495251645878\ \(0\)\
\-\ or\\:\\ 0\\.004000756653649963\ \(0\)\
\-\ to\\:\\ 0\\.003980661463516517\ \(0\)\
\-\ cerebral\\:\\ 0\\.003942005994359616\ \(0\)\
\-\ presentation\\:\\ 0\\.0039193084347417875\ \(0\)\
\-\ given\\:\\ 0\\.0039006849434305496\ \(0\)\
\-\ 3\\.\\:\\ 0\\.003893307872357826\ \(0\)\
\-\ areas\\:\\ 0\\.0038286913065859744\ \(0\)\
\-\ available\\:\\ 0\\.0038251918093738977\ \(0\)\
\-\ recent\\:\\ 0\\.0038251918093738977\ \(0\)\
\-\ by\\:\\ 0\\.0037892700485882154\ \(0\)\
\-\ along\\:\\ 0\\.003760391314059276\ \(0\)\
\-\ study\\:\\ 0\\.003743850009134433\ \(0\)\
\-\ positive\\:\\ 0\\.003692257776676587\ \(0\)\
\-\ superior\\:\\ 0\\.0036334802890202285\ \(0\)\
\-\ 2\\.\\:\\ 0\\.0036184342766980805\ \(0\)\
\-\ area\\:\\ 0\\.0035976514569031524\ \(0\)\
\-\ adjacent\\:\\ 0\\.0035976514569031524\ \(0\)\
\-\ bowel\\:\\ 0\\.00356851335936719\ \(0\)\
\-\ 1\\.\\:\\ 0\\.003554179981754462\ \(0\)\
\-\ approximately\\:\\ 0\\.0035203965733096977\ \(0\)\
\-\ her\\:\\ 0\\.003421320450712298\ \(0\)\
\-\ only\\:\\ 0\\.003421320450712298\ \(0\)\
\-\ there\\:\\ 0\\.003386725849440716\ \(0\)\
\-\ level\\:\\ 0\\.0032794793976656886\ \(0\)\
\-\ changes\\:\\ 0\\.0032610492359987494\ \(0\)\
\-\ focal\\:\\ 0\\.0032496585940591243\ \(0\)\
\-\ abnormal\\:\\ 0\\.003245129481111733\ \(0\)\
\-\ edema\\:\\ 0\\.0032182736210802807\ \(0\)\
\-\ likely\\:\\ 0\\.0032094407003137905\ \(0\)\
\-\ secondary\\:\\ 0\\.003181131779638892\ \(0\)\
\-\ y\\/o\\:\\ 0\\.0031513036349129706\ \(0\)\
\-\ shows\\:\\ 0\\.003128327163420611\ \(0\)\
\-\ blood\\:\\ 0\\.0031057404427553923\ \(0\)\
\-\ \\:\\:\\ 0\\.0030100527722787354\ \(0\)\
\-\ signal\\:\\ 0\\.00300009897506362\ \(0\)\
\-\ common\\:\\ 0\\.0029777193235105155\ \(0\)\
\-\ these\\:\\ 0\\.0029611780185856726\ \(0\)\
\-\ more\\:\\ 0\\.002845774047020195\ \(0\)\
\-\ acute\\:\\ 0\\.0028094265367596474\ \(0\)\
\-\ physical\\:\\ 0\\.002791618201839199\ \(0\)\
\-\ increased\\:\\ 0\\.002783601573634695\ \(0\)\
\-\ imaging\\:\\ 0\\.0026658772629235723\ \(0\)\
\-\ 3\\:\\ 0\\.0026644148158542474\ \(0\)\
\-\ woman\\:\\ 0\\.002628366108507199\ \(0\)\
\-\ most\\:\\ 0\\.0026269442632863866\ \(0\)\
\-\ other\\:\\ 0\\.002622687814517242\ \(0\)\
\-\ small\\:\\ 0\\.0026212720164861766\ \(0\)\
\-\ demonstrate\\:\\ 0\\.0026184449285393354\ \(0\)\
\-\ mri\\:\\ 0\\.0026142155191939014\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0026128086961124102\ \(0\)\
\-\ contrast\\:\\ 0\\.002546971620250207\ \(0\)\
\-\ left\\:\\ 0\\.0025462190926043003\ \(0\)\
\-\ exam\\:\\ 0\\.0024996457256318753\ \(0\)\
\-\ lateral\\:\\ 0\\.002458945466876898\ \(0\)\
\-\ but\\:\\ 0\\.0024267687097650303\ \(0\)\
\-\ findings\\:\\ 0\\.002421886732077177\ \(0\)\
\-\ female\\:\\ 0\\.0023392280578533073\ \(0\)\
\-\ no\\:\\ 0\\.002291462451940884\ \(0\)\
\-\ patient\\:\\ 0\\.002281203544384522\ \(0\)\
\-\ for\\:\\ 0\\.0019416994637622242\ \(0\)\
\-\ on\\:\\ 0\\.0019278056254738432\ \(0\)\
\-\ be\\:\\ 0\\.0017546694052515703\ \(0\)\
\-\ with\\:\\ 0\\.001713776214365895\ \(0\)\
\-\ not\\:\\ 0\\.001644232585541858\ \(0\)\
\-\ an\\:\\ 0\\.001573455212096844\ \(0\)\
\-\ this\\:\\ 0\\.001279809871257168\ \(0\)\
\-\ \\.\\:\\ 0\\.0012290119021717751\ \(0\)\
